Sensorium Therapeutics
Franz Nimrod Aurelio, CPA, is an accomplished tax analyst currently working at Chevron since April 2022, specializing in US tax compliance and reporting, with responsibilities including handling US 1099 information reporting and vendor master reviews. Prior experience includes serving as a Senior Analyst at Deutsche Bank from September 2018 to July 2021, where contributions included quality assurance in US wealth management financials and UK regulatory reporting. Earlier roles included an Assurance Associate II position at SGV & Co. from June 2016 to January 2018, where Franz excelled in audit engagements and mentored new associates. Franz holds a Bachelor of Science in Accountancy from the University of Santo Tomas, earned in 2015.
This person is not in the org chart
This person is not in any offices
Sensorium Therapeutics
Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world.